[Pharmacokinetics of indomethacin and indomethacin metabolites administered continuously to patients with healthy or damaged kidneys].
After oral administration of 75 mg Indomethacin dlimination half-life of the unchanged drug is not altered in patients with severely impaired renal function. In patients with renal insufficiency half-life of Indomethacin plus metabolites is twice that of the normal value. Repeated daily administration of 75 mg for 8 days does not influence Indomethacin kinetics. In the control group and in patients with moderate by impaired renal function Indomethacin half-life does not change during chronic administration.
D006207:Half-Life; D006801:Humans; D007213:Indomethacin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism*; D007674:Kidney Diseases / Q000378:metabolism*; D007700:Kinetics; D013997:Time Factors
D007213:Indomethacin
Zur Pharmakokinetik von Indomethazin und Indomethazin-metaboliten bei wiederholter Applikation an nierengesunden und nierengeschädigten Patienten.